Evaxion(EVAX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company reported a net loss of $7.7 million for 2025, an improvement compared to the previous year [25] - Cash position at the end of the year was $23 million, extending the cash runway into the second half of 2027 [26] - Total cash inflow for the year amounted to $32 million, driven by public offerings and the exercise of investor warrants [21][22] Business Line Data and Key Metrics Changes - The EVX-01 program, a personalized cancer vaccine, showed a high objective response rate of 75% and a complete response rate of 25% in a two-year phase 2 study [11] - The EVX-04 program for acute myeloid leukemia (AML) demonstrated strong preclinical evidence, with 16 optimal ERV antigen fragments identified [14] - The EVX-B2 program for gonorrhea retained full global rights, with strong preclinical data indicating significant protection in mouse models [16] Market Data and Key Metrics Changes - The company has seen significant interest in its AI-Immunology platform from various parties, including collaborations with MSD and The Gates Foundation [4][7] - The autoimmune disease market is being explored, with over 14 million patients affected annually in the U.S. [8] Company Strategy and Development Direction - The company aims to optimize its focus on assets that will add the most value, particularly in oncology and infectious diseases [34] - There is a commitment to deriving value from both the platform and pipeline assets through partnerships [9] - The AI-Immunology platform is being investigated for applications in autoimmune diseases, with plans to identify key indications for development [8][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strength of the AI-Immunology platform and its ability to generate meaningful clinical responses [33] - The company is positioned to advance through 2026, with ongoing discussions for potential partnerships [28] - Management highlighted the importance of building relationships and credibility with large pharmaceutical companies [62] Other Important Information - The company received recognition from the Galien Foundation for advances in AI in human health [6] - The automated vaccine design module launched in October 2025 enhances the design process, reducing costs and development time [19] Q&A Session Summary Question: Changes to strategy under new CEO - The fundamentals of the company remain strong, with a focus on optimizing value in oncology and infectious disease assets [34] Question: Regulatory submission for EVX-04 - The company is preparing for clinical trials and believes initial proof of concept will attract partner interest [36] Question: Partnering efforts for EVX-01 - The company is seeing interest in the cancer vaccine space, particularly due to strong clinical data and translational insights [46] Question: Application of AI-Immunology in autoimmune diseases - The company is analyzing prevalent autoimmune diseases to determine the best fit for its platform [76]